Dendritic cell-based adjuvant vaccination targeting wilms’tumor 1 in patients with advanced colorectal cancer

Vaccines

Volumn 3, Issue 4, 2015, Pages 1004-1018

  Shimodaira, Shigetaka ^a   Sano, Kenji ^a   Hirabayashi, Koichi ^a   Koya, Terutsugu ^a   Higuchi, Yumiko ^a   Mizuno, Yumiko ^a   Yamaoka, Naoko ^a   Yuzawa, Miki ^a   Kobayashi, Takashi ^a   Ito, Kenichi ^a   Koizumi, Tomonobu ^a  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Dendritic cell vaccines; Enzyme linked immunosorbent spot assay; Immunohistochemistry; Tetramer analysis; Wilms tumor 1

Indexed keywords

ADJUVANT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HLA ANTIGEN CLASS 1; METHOTREXATE; OXALIPLATIN; PICIBANIL; TETRAMER; WT1 PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CASE REPORT; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEMICOLECTOMY; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METRONOMIC DRUG ADMINISTRATION; OVARY METASTASIS; PROTEIN EXPRESSION; RECTUM CANCER;

EID: 85016922172     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3041004     Document Type: Article

References (48)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. 2010 Cancer statistics. CA Cancer J. Clin. 2010, 60, 277–300.
2. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. Available online: http://ganjoho.jp/en/professional/statistics/table_download.html (accessed on 31 March 2015).
3. Matsuda, A.; Matsuda, T.; Shibata, A.; Katanoda, K.; Sobue, T.; Nishimoto, H. The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn. J. Clin. Oncol. 2013, 44, 388–396.
4. Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723.
5. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454.
6. Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369, 134–144.
7. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455–2465.
8. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369, 122–133.
9. Weber, J.S.; Kudchadkar, R.R.; Yu, B.; Gallenstein, D.; Horak, C.E.; Inzunza, H.D.; Zhao, X.; Martinez, A.J.; Wang, W.; Gibney, G.; et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 2013, 31, 4311–4318.
10. Steinman, R.M. Decisions about dendritic cells: Past, present, and future. Annu. Rev. Immunol. 2012, 30, doi: 10.1146/annurev-immunol-100311-102839.
11. Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15, 5323–5337.
12. Nair, S.K.; Boczkowski, D.; Morse, M.; Cumming, R.I.; Lyerly, H.K.; Gilboa, E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 1998, 16, 364–369.
13. Morse, M.A.; Deng, Y.; Coleman, D.; Hull, S.; Kitrell-Fisher, E.; Nair, S.; Schlom, J.; Ryback, M.E.; Lyerly, H.K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 1999, 5, 1331–1338.
14. Nair, S.K.; Hull, S.; Coleman, D.; Gilboa, E.; Lyerly, H.K.; Morse, M.A. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 1999, 82, 121–124.
15. Fong, L.; Hou, Y.; Rivas, A.; Benike, C.; Yuen, A.; Fisher, G.A.; Davis, M.M.; Engleman, E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 2001, 98, 8809–8814.
16. Liu, K.J.; Wang, C.C.; Chen, L.T.; Cheng, A.L.; Lin, D.T.; Wu, Y.C.; Yu, W.L.; Hung, Y.M.; Yang, H.Y.; Juang, S.H.; et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 2004, 10, 2645–2651.
17. Lesterhuis, W.J.; de Vries, I.J.; Schuurhuis, D.H.; Boullart, A.C.; Jacobs, J.F.; de Boer, A.J.; Scharenborg, N.M.; Brouwer, H.M.; van de Rakt, M.W.; Figdor, C.G.; et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann. Oncol. 2006, 17, 974–980.
18. Oka, Y.; Elisseeva, O.A.; Tsuboi, A.; Ogawa, H.; Tamaki, H.; Li, H.; Oji, Y.; Kim, E.H.; Soma, T.; Asada, M.; et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics 2000, 51, 99–107.
19. Ohminami, H.; Yasukawa, M.; Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95, 286–293.
20. Tsuboi, A.; Oka, Y.; Udaka, K.; Murakami, M.; Masuda, T.; Nakano, A.; Nakajima, H.; Yasukawa, M.; Hiraki, A.; Oji, Y.; et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol. Immunother. 2002, 51, 614–620.
21. Kimura, Y.; Tsukada, J.; Tomoda, T.; Takahashi, H.; Imai, K.; Shimamura, K.; Sunamura, M.; Yonemitsu, Y.; Shimodaira, S.; Koido, S.; et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012, 41, 195–205.
22. Takahashi, H.; Okamoto, M.; Shimodaira, S.; Tsujitani, S.; Nagaya, M.; Ishidao, T.; Kishimoto, J.; Yonemitsu, Y. DC-Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT). Impact of dendritic cell vaccines pulsed with Wilms’ tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur. J. Cancer 2013, 49, 852–859.
23. Kobayashi, M.; Sakabe, T.; Abe, H.; Tanii, M.; Takahashi, H.; Chiba, A.; Yanagida, E.; Shibamoto, Y.; Ogasawara, M.; Tsujitani, S.; et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J. Gastrointest. Surg. 2013, 17, 1609–1617.
24. Kobayashi, M.; Shimodaira, S.; Nagai, K.; Ogasawara, M.; Takahashi, H.; Abe, H.; Tanii, M.; Okamoto, M.; Tsujitani, S.; Yusa, S.; et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: A multicenter analysis. Cancer Immunol. Immunother. 2014, 63, 797–806.
25. Koido, S.; Homma, S.; Okamoto, M.; Takakura, K.; Mori, M.; Yoshizaki, S.; Tsukinaga, S.; Odahara, S.; Koyama, S.; Imazu, H.; et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res. 2014, 20, 4228–4239.
26. Kobayashi, M.; Chiba, A.; Izawa, H.; Yanagida, E.; Okamoto, M.; Shimodaira, S.; Yonemitsu, Y.; Shibamoto, Y.; Suzuki, N.; Nagaya, M.; et al. The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J. Ovarian Res. 2014, doi:10.1186/1757-2215-7-48.
27. Kobayashi, M.; Sakabe, T.; Chiba, A.; Nakajima, A.; Okamoto, M.; Shimodaira, S.; Yonemitsu, Y.; Shibamoto, Y.; Suzuki, N.; Nagaya, M. Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: A case report. World J. Surg. Oncol. 2014, doi:10.1186/1477-7819-12-390.
28. Sakai, K.; Shimodaira, S.; Maejima, S.; Udagawa, N.; Sano, K.; Higuchi, Y.; Koya, T.; Ochiai, T.; Koide, M.; Uehara, S.; et al. Dendritic cell-based immunotherapy targeting Wilms’ Tumor 1 (WT1) in patients with relapsed malignant glioma. J. Neurosurg. 2015, 123, 989–997.
29. Fujiki, F.; Oka, Y.; Tsuboi, A.; Kawakami, M.; Kawakatsu, M.; Nakajima, H.; Elisseeva, O.A.; Harada, Y.; Ito, K.; Li, Z.; et al. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J. Immunother. 2007, 30, 282–293.
30. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10, 909–915.
31. Hoos, A. Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 2012, 8, 47–52.
32. Schlom, J.; Arlen, P.M.; Gulley, J.L. Cancer vaccines: Moving beyond current paradigms. Clin. Cancer Res. 2007, 13, 3776–3782.
33. Duffy, A.G.; Greten, T.F. Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann. Oncol. 2014, 25, 24–32.
34. Shibamoto, Y.; Okamoto, M.; Kobayashi, M.; Ayakawa, S.; Iwata, H.; Sugie, C.; Mitsuishi, Y.; Takahashi, H. Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. Mol. Clin. Oncol. 2013, 1, 649–654.
35. Shimodaira, S.; Kobayashi, T.; Hirabayashi, K.; Horiuchi, K.; Koya, T.; Mizuno, Y.; Yamaoka, N.; Yuzawa, M.; Ishikawa, S.; Higuchi, Y.; et al. Induction of antigen-specific cytotoxic T lymphocytes by chemoradiotherapy in patients receiving Wilms’ tumor 1-targetted dendritic cell vaccinations for pancreatic cancer. OMICS J. Radiol. 2015, doi:10.4172/2167-7964.1000196.
36. Shimodaira, S.; Hirabayashi, K.; Kobayashi, T.; Higuchi, Y.; Yokokawa, K. Future Prospective of Cancer Vaccination Technology in Japan. Pharmaceut. Reg. Affairs 2015, 4, doi:10.4172/2167-7689.1000143.
37. Shimodaira, S.; Higuchi, Y.; Koya, T.; Kobayashi, T.; Yanagisawa, R.; Hirabayashi, K.; Ito, K.; Koizumi, T.; Maejima, S.; Udagawa, N. Smoking influences the yield of dendritic cells for cancer immunotherapy. Pharmaceut. Reg. Affairs 2015, doi:10.4172/2167-7689.1000133.
38. Nakatsuka, S.; Oji, Y.; Horiuchi, T.; Kanda, T.; Kitagawa, M.; Takeuchi, T.; Kawano, K.; Kuwae, Y.; Yamauchi, A.; Okumura, M.; et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 2006, 19, 804–814.
39. Higuchi, Y.; Koya, T.; Yuzawa, M.; Yamaoka, N.; Mizuno, Y.; Yoshizawa, K.; Hirabayashi, K.; Kobayashi, T.; Sano, K.; Shimodaira, S. Enzyme-linked immunosorbent spot assay for the detection of Wilms’ tumor 1-specific T cells induced by dendritic cell vaccination. Biomedicines 2015, 3, 304–315.
40. Koido, S.; Ohkusa, T.; Homma, S.; Namiki, Y.; Takakura, K.; Saito, K.; Ito, Z.; Kobayashi, H.; Kajihara, M.; Uchiyama, K.; et al. Immunotherapy for colorectal cancer. World J. Gastroenterol. 2013, 19, 8531–8542.
41. Nishikawa, H.; Sakaguchi, S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 127, 759–767.
42. Whiteside, T.L. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin. Biol. Ther. 2014, 14, 1411–1425.
43. Nagaraj, S.; Gabrilovich, D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68, 2561–2563.
44. Ezzelarab, M.; Thomson, A.W. Tolerogenic dendritic cells and their role in transplantation. Semin. Immunol. 2011, 23, 252–263.
45. Svajger, U.; Rozman, P. Tolerogenic dendritic cells: Molecular and cellular mechanisms in transplantation. J. Leukoc. Biol. 2014, 95, 53–69.
46. Massagué, J. TGFbeta in Cancer. Cell 2008, 134, 215–230.
47. Shih, K.; Arkenau, H.T.; Infante, J.R. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014, 74, 1993–2013.
48. Oji, Y.; Ogawa, H.; Tamaki, H.; Oka, Y.; Tsuboi, A.; Kim, E.H.; Soma, T.; Tatekawa, T.; Kawakami, M.; Asada, M.; et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 1999, 90, 194–204.